Wave Life Sciences (WVE) to Release Quarterly Earnings on Wednesday

Wave Life Sciences (NASDAQ:WVE) is expected to post its quarterly earnings results before the market opens on Wednesday, March 5th. Analysts expect Wave Life Sciences to post earnings of ($0.18) per share and revenue of $25.60 million for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Wave Life Sciences Trading Down 1.1 %

WVE stock opened at $10.36 on Wednesday. The stock has a market capitalization of $1.58 billion, a P/E ratio of -9.33 and a beta of -1.09. Wave Life Sciences has a 12 month low of $4.25 and a 12 month high of $16.74. The firm has a 50-day moving average price of $11.90 and a 200-day moving average price of $11.02.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on WVE shares. Jefferies Financial Group started coverage on shares of Wave Life Sciences in a research report on Tuesday. They set a “buy” rating and a $26.00 target price for the company. Mizuho lifted their price target on shares of Wave Life Sciences from $19.00 to $22.00 and gave the company an “outperform” rating in a research report on Thursday, November 21st. B. Riley lifted their price target on shares of Wave Life Sciences from $19.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, November 4th. HC Wainwright restated a “buy” rating and set a $22.00 price objective on shares of Wave Life Sciences in a research note on Wednesday, November 13th. Finally, Truist Financial raised their price objective on Wave Life Sciences from $17.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, November 12th. One analyst has rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $22.60.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.